Herpes simplex: Insights on pathogenesis and possible vaccines

Annual Review of Medicine

Volumn 59, Issue , 2008, Pages 381-395

  Koelle, David M ^a,b,c   Corey, Lawrence ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

Herpes simplex virus; Human immunodeficiency virus; Lymphocyte; Vaccine

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HERPES SIMPLEX VACCINE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR 2;

DISEASE SEVERITY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INNATE IMMUNITY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS;

EID: 39649109256     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.59.061606.095540     Document Type: Review

References (83)

1. Xu F, Sternberg MR, Kottiri BJ, et al. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-73
2. Roizman B, Knipe DM, Whitley RJ. 2007. Herpes simplex viruses. In Fields Virology, ed. DM Knipe, PM Howley, pp. 2501-602. Philadelphia: Lippincott, Williams, and Wilkins
3. Corey L, Wald A. 1999. Genital herpes. In Sexually Transmitted Diseases, ed. KK Holmes, PF Sparling, PA Mardh, et al., pp. 285-312. New York: McGraw-Hill
4. Kimberlin DW. 2005. Herpes simplex virus infections in neonates and early childhood. Semin. Pediatr. Infect. Dis. 16:271-81
5. Dupuis S, Jouanguy E, Al-Hajjar S, et al. 2 003. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33:388-91
6. Dorsky DI, Crumpacker CS. 1987. Drugs five years later: acyclovir. Ann. Intern. Med. 107:859-74
7. Workowski KA, Berman SM. 2006. Sexually transmitted diseases treatment guidelines, 2006. Morb. Mortal. Wkly. Rep. 55(RR-11):16-22
8. Corey L. 2004. Herpes simplex viruses. In Harrison's Principles of Internal Medicine, ed. DL Kasper, E Braunwald, AS Fauci, et al., pp. 1035-42. New York: McGraw-Hill
9. Corey L. 2007. Synergistic copathogens - HIV-1 and HSV-2. N. Engl. J. Med. 356:854-56
10. Corey L. 2007. Herpes simplex virus type 2 and HIV-1: the dialogue between the 2 organisms continues. J. Infect. Dis. 195:1242-44
11. Freeman EE, Weiss HA, Glynn JR, et al. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83
12. Beyrer C, Jitwatcharanan K, Natpratan C, et al. 1998. Molecular methods for the diagnosis of genital ulcer disease in a sexually transmitted disease clinic population in northern Thailand: predominance of herpes simplex virus infection. J. Infect. Dis. 178:243-46
13. Hoyo C, Hoffman I, Moser BK, et al. 2005. Improving the accuracy of syndromic diagnosis of genital ulcer disease in Malawi. Sex. Transm. Dis. 32:231-37
14. Lai W, Chen CY, Morse SA, et al. 2003. Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa. Sex. Transm. Infect. 79:202-7
15. Schacker T, Ryncarz AJ, Goddard J, et al. 1998. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280:61-66
16. Nagot N, Ouedraogo A, Foulongne V, et al. 2007. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N. Engl. J. Med. 356:790-99
17. Ouedraogo A, Nagot N, Vergne L, et al. 2006. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 20:2305-13
18. Celum CL, Robinson NJ, Cohen MS. 2005. Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J. Infect. Dis. 191(Suppl. 1):S107-14
19. Kapiga SH, Sam NE, Bang H, et al. 2007. The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J. Infect. Dis. 195:1260-69
20. Gray RH, Li X, Wawer MJ, et al. 2004. Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. J. Infect. Dis. 189:1209-15
21. + lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126:946-54
22. Langenberg AGM, Corey L, Ashley RL, et al. 2000. A prospective study of new infections with herpes simplex virus type 1 and type 2. N. Engl. J. Med. 341:1432-38
23. Mertz GJ, Schmidt O, Jourden JL, et al. 1985. Frequency of acquisition of first-episode genital infection with herpes simplex virus from asymptomatic and symptomatic source contacts. Sex. Transm. Dis. 12:33-39
24. Langenberg A, Benedetti J, Jenkins J, et al. 1989. Development of clinically recognizable genital lesions among women previously identified as having asymptomatic herpes simplex virus type 2 infection. Ann. Intern. Med. 110:882-87
25. Frenkel LM, Garratty EM, Shen JP, et al. 1993. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. Ann. Intern. Med. 118:414-18
26. Wald A, Langenberg AG, Krantz E, et al. 2005. The relationship between condom use and herpes simplex virus acquisition. Ann. Intern. Med. 143:707-13
27. Brown EL, Wald A, Hughes JP, et al. 2006. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am. J. Epidemiol. 164:733-41
28. Wald A, Corey L, Cone R, et al. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J. Clin. Invest. 99:1092-97
29. Corey L, Wald A, Patel R, et al. 2004. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N. Engl. J. Med. 350:11-20
30. Koelle DM, Benedetti J, Langenberg A, Corey L. 1992. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital infection. Ann. Intern. Med. 116:433-37
31. Engelberg R, Carrell D, Krantz E, et al. 2003. Natural history of genital herpes simplex virus type 1 infection. Sex. Transm. Dis. 30:174-77
32. Siegal FP, Kadowaki N, Shodell M, et al. 1999. The nature of the principle type 1 interferon-producing cells in human blood. Science 284:1835-37
33. Chehimi J, Campbell DE, Azzoni L, et al. 2002. Persistent decreases in blood plasma-cytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J. Immunol. 168:4796-801
34. Abbo L, Vincek V, Dickinson G, et al. 2007. Selective defect in plasmacytoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Clin. Infect. Dis. 44:e25-27
35. Dalloul A, Oksenhendler E, Chosidow O, et al. 2004. Severe herpes virus (HSV-2) infection in two patients with myelodysplasia and undetectable NK cells and plasmacytoid dendritic cells in the blood. J. Clin. Virol. 30:329-36
36. Lund J, Sato A, Akira S, et al. 2003. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J. Exp. Med. 198:513-20
37. Zhao X, Deak E, Soderberg K, et al. 2003. Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2. J. Exp. Med. 197:153-62
38. + dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196:1099-104
39. Lund JM, Linehan MM, Iijima N, et al. 2006. Cutting edge: plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J. Immunol. 177:7510-14
40. Leib DA. 2002. Counteraction of interferon-induced antiviral responses by herpes simplex viruses. Curr. Top. Microbiol. Immunol. 269:171-85
41. Lin R, Noyce RS, Collins SE, et al. 2004. The herpes simplex virus ICP0 RING finger domain inhibits IRF3- and IRF7-mediated activation of interferon-stimulated genes. J. Virol. 78:1675-84
42. Sanchez R, Mohr I. 2007. Inhibition of cellular 2′-5′ oligoadenylate synthetase by the herpes simplex virus type 1 Us11 protein. J. Virol. 81:3455-64
43. Koelle DM, Posavad CM, Barnum GR, et al. 1998. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J. Clin. Invest. 101:1500-8
44. Verjans GM, Roest RW, Van Der Kooi A, et al. 2004. Isopentenyl pyrophosphate-reactive Vgamma9Vdelta 2 T helper 1-like cells are the major gammadelta T cell subset recovered from lesions of patients with genital herpes. J. Infect. Dis. 190:489-93
45. Sciammas R, Johnson RM, Sperling AI, et al. 1994. Unique recognition by a herpesvirus-specific TCRgd cell. J. Immunol. 152:5392-97
46. Yasukawa M, Zarling JM. 1983. Autologous herpes simplex virus-infected cells are lysed by human natural killer cells. J. Immunol. 131:2011-16
47. Hargett D, Rice S, Bachenheimer SL. 2006. Herpes simplex virus type 1 ICP27-dependent activation of NF-kappaB. J. Virol. 80:10565-78
48. Sato A, Linehan MM, Iwasaki A. 2006. Dual recognition of herpes simplex viruses by TLR2 and TLR9 in dendritic cells. Proc. Natl. Acad. Sci. USA 103:17343-48
49. Niehues T, Reichenbach J, Neubert J, et al. 2004. Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. J. Allergy Clin. Immunol. 114:1456-62
50. Casrouge A, Zhang SY, Eidenschenk C, et al. 2006. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 314:308-12
51. Jawahar S, Moody C, Chan M, et al. 1996. Natural killer (NK) cell deficiency associated with an epitope-deficient Fc receptor type IIIA (CD16-II). Clin. Exp. Immunol. 103:408-13
52. Garcia-Perez MA, Paz-Artal E, Correll A, et al. 2003. Mutations of CD40L ligand in two patients with hyper-IgM syndrome. Immunobiology 207:285-94
53. Bochud PY, Magaret AS, Koelle DM, et al. 2007. Increased viral shedding and lesional rate in patients with genital HSV-2 infection. J. Infect. Dis. 196:505-9
54. Mark KE, Corey L, Meng T-C, et al. 2007. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195:1324-31
55. Wu JJ, Huang DB, Tyring SK. 2004. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antivir. Res. 64:79-83
56. + lymphocytes. J. Virol. 80:2863-72
57. Smith CM, Wilson NS, Waithman J, et al. 2004. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat. Immunol. 5:1143-48
58. Milligan GN, Bernstein DI, Bourne N. 1998. T lymphocytes are required for protection of the vaginal mucosae and sensory ganglia of immune mice against reinfection with herpes simplex virus type 2. J. Immunol. 160:6093-100
59. + cytotoxic T lymphocyte responses. Proc. Natl. Acad. Sci. USA 94:10289-94
60. Schacker T, Zeh J, Hu H-L, et al. 1998. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J. Infect. Dis. 178:1616-22
61. Posavad CM, Wald A, Kuntz S, et al. 2004. Frequent reactivation of herpes simplex virus among HIV-1-infected patients treated with highly active antiretroviral therapy. J. Infect. Dis. 190:693-96
62. Koelle DM, Abbo H, Peck A, et al. 1994. Direct recovery of HSV-specific T lymphocyte clones from human recurrent HSV-2 lesions. J. Infect. Dis. 169:956-61
63. Cunningham AL, Turner RR, Miller AC, et al. 1985. Evolution of recurrent herpes simplex lesions: an immunohistologic study. J. Clin. Invest. 75:226-33
64. Orr MT, Orgun NN, Wilson CB, et al. 2007. Cutting edge: recombinant listeria monocytogenes expressing a single immune-dominant peptide confer immunity to herpes simplex virus-1 infection. J. Immunol. 178:4731-35
65. + T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 18:593-603
66. Verjans GMGM, Hintzen RQ, van Dun JM, et al. 2007. Selective retention of herpes simplex virus specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. USA 104:3496-501
67. + T cells in the latently infected trigeminal ganglia. J. Immunol. 176:1703-11
68. + regulatory T cells control the severity of viral immunoinflammatory lesions. J. Immunol. 172:4123-32
69. + T-cells specific for a skin-tropic virus. J. Clin. Invest. 110:537-48
70. + T cells contiguous to sensory nerve endings limit HSV-2 reactivation in human genital skin. J. Exp. Med. 204:595-603
71. Koelle DM, Liu Z, McClurkan CL, et al. 2003. Immunodominance among herpes simplex virus-specific CD8 T-cells expressing a tissue-specific homing receptor. Proc. Natl. Acad. Sci. USA 100:12899-904
72. + T cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 80:5509-15
73. Messaoudi I, Guevara Patino JA, Dyall R, et al. 2002. Direct link between MHC polymorphism, T cell avidity, and diversity in immune defense. Science 298:1797-800
74. Brown ZA, Gardella C, Wald A, et al. 2005. Genital herpes complicating pregnancy. Obstet. Gynecol. 106:845-56
75. Corey L, Langenberg AGM, Ashley R, et al. 1999. Two double-blind, placebo-controlled trials of a vaccine containing recombinant gD2 and gB2 antigens in MF59 adjuvant for the prevention of genital HSV-2 acquisition. JAMA 282:331-40
76. Lubinski JM, Jiang M, Hook L, et al. 2002. Herpes simplex virus type 1 evades the effects of antibody and complement in vivo. J. Virol. 76:9232-41
77. Spear PG. 2004. Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol. 6:401-10
78. Heldwein EE, Lou H, Bender FC, et al. 2006. Crystal structure of glycoprotein B from herpes simplex virus 1. Science 313:217-20
79. Stanberry LR, Spruance SL, Cunningham AL. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. GlaxoSmithKline Herpes Vaccine Efficacy Study Group. N. Engl. J. Med. 347:1652-61
80. Sucato G, Wald A, Wakabayashi E, et al. 1998. Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. J. Infect. Dis. 177:1069-72
81. Gupta A, Gartner JJ, Sethupathy P, et al. 2006. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nature 442:82-85
82. Langenberg AGM, Corey RL, Ashley RL, et al. 1999. Acquisition of symptomatic and asymptomatic HSV-1 and HSV-2 infections: a prospective study of their incidence and clinical spectrum. N. Engl. J. Med. 341:1432-38
83. Brandt CR, Kolb AW, Shah DD, et al. 2003. Multiple determinants contribute to the virulence of HSV ocular and CNS infection and identification of serine 34 of the US1 gene as an ocular disease determinant. Invest. Ophthalmol. Vis. Sci. 44:2657-68